Sana Biotechnology (NASDAQ:SANA) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Sana Biotechnology (NASDAQ:SANA) in a research note published on Friday, MarketBeat reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

Several other analysts have also commented on the company. HC Wainwright lifted their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.25.

Sana Biotechnology Trading Up 10.6 %

Shares of SANA stock opened at $2.93 on Friday. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50. The stock has a market capitalization of $654.18 million, a P/E ratio of -2.09 and a beta of 1.63. The firm’s 50 day moving average is $3.03 and its 200 day moving average is $3.25.

Insider Buying and Selling

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 31.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Sana Biotechnology

Several large investors have recently added to or reduced their stakes in SANA. Cerity Partners LLC purchased a new stake in shares of Sana Biotechnology in the fourth quarter worth $25,000. Tower Research Capital LLC TRC increased its stake in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after buying an additional 10,548 shares in the last quarter. Syon Capital LLC bought a new stake in Sana Biotechnology during the fourth quarter valued at about $27,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Sana Biotechnology in the third quarter valued at about $29,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of Sana Biotechnology in the fourth quarter valued at about $29,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.